Rat Paw Model

Carrageenan triggers the release of inflammatory mediators after injection into the paw. These mediators increase vascular permeability, allowing fluid to move into surrounding tissue and produce edema, or swelling. The resulting increase in paw thickness or volume provides a quantitative indication of the inflammatory response and allows investigators to examine how candidate compounds alter that response.

Increased vascular permeability links mediator activity to the visible and measurable accumulation of fluid in paw tissue. Because this process contributes directly to edema, changes in paw thickness or volume can reflect differences in inflammatory intensity. Measuring swelling therefore gives researchers a practical endpoint for connecting local tissue responses with the effects of potential anti-inflammatory treatments.

Edema measurements describe tissue swelling, whereas thermal and mechanical assessments capture pain-related sensitivity. Using these endpoints together helps distinguish a compound’s effects on inflammation from its effects on pain behavior. A treatment may be evaluated for its ability to reduce swelling, lessen sensitivity, or influence both responses, providing a broader assessment than either endpoint alone.

A typical workflow begins with injecting an inflammatory agent, such as carrageenan, into the rat paw. Investigators then quantify paw thickness or volume and assess thermal or mechanical pain behaviors. Candidate therapeutic compounds can be compared through these measurements to determine whether they modify inflammation, swelling, pain sensitivity, or a combination of these outcomes.

The principal physical readouts are paw thickness and paw volume, which quantify edema after inflammatory stimulation. Thermal and mechanical pain behaviors provide complementary functional measures of sensitivity. Together, these endpoints generate quantitative data for evaluating inflammatory and analgesic effects rather than relying only on qualitative observations of tissue swelling or discomfort.

This model supports investigation of inflammatory mechanisms and enables comparison of candidate treatments under the same general experimental framework. By measuring both local swelling and pain-related behavior, researchers can assess drug efficacy across related outcomes. Its findings can contribute to early therapeutic evaluation before compounds proceed to more advanced preclinical studies.